The role of Serum Visfatin as Diagnostic Marker of Active Inflammatory Bowel Disease

Authors

1 Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia, Egypt

2 Clinical pathology, National Liver Institute, Menoufia University, Menoufia, Egypt

3 pathology, National Liver Institute, Menoufia University, Menoufia, Egypt

Abstract

Background: The mucosal immune system's degradation of the gastrointestinal tract mucosa is the underlying cause of inflammatory bowel diseases (IBDs). Aim of the Work: The goals of this research are to ascertain visfatin serum concentrations in newly diagnosed IBD patients and assess visfatin's diagnostic value alongside disease activity and colonoscopic findings. Patients and Methods: This case-control research was conducted at the outpatient clinic of Alexandria Fever Hospital. 90 subjects were included and categorized into three groups: 30 patients newly diagnosed with Crohn's disease,30 cases newly diagnosed with ulcerative colitis, and 30 case-control individuals matched for age and sex. All groups were evaluated by clinical findings, gastrointestinal endoscopy with histopathology, and laboratory investigations, including serum visfatin and inflammatory markers. Results: This research demonstrated that there was an incredibly significant variance among Crohn's disease, Ulcerative colitis, and control as regards serum visfatin, fecal calprotectin, ESR, and CRP. The sensitivity and specificity of serum visfatin at a cutoff point ≥2.25 were 76.7% and 86.7%, respectively, for the detection of Crohn's disease with 0.891 AUC, p Conclusion: This research discovered that elevated visfatin levels were associated with newly diagnosed active colonic inflammatory disorder. Serum visfatin is one potential new indicator for predicting activity and severity in inflammatory bowel disease patients.

Files

Share

How to cite

Statistics